HopeStage
Back to all studies
CompletedEUCTR 2006-004783-31

A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Dos...

This historical record does not confirm current site availability.

Historical research recordHungary + LatviaSchizophrenia
The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations
Hungary · Latvia
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
80
Sponsor
AstraZeneca AB
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Hungary, Latvia
Age range
Not clearly listed
Official registry ID
EUCTR 2006-004783-31
Official title
Show the full official title

A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Dos...

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Hungary · Latvia

Registry details
Historical country statuses
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca AB.

Want to explore more studies?

Explore studies